Benefit-risk assessment of orlistat in the treatment of obesity.

Benefit-risk assessment of orlistat in the treatment of obesity.

Item
http://www.wikidata.org/entity/Q38234236
Next generation of weight management medications: implications for diabetes and CVD riskBeneficial effects of training at the anaerobic threshold in addition to pharmacotherapy on weight loss, body composition, and exercise performance in women with obesity.Ferulic acid lowers body weight and visceral fat accumulation via modulation of enzymatic, hormonal and inflammatory changes in a mouse model of high-fat diet-induced obesityTherapies for inter-relating diabetes and obesity - GLP-1 and obesity.Chemical Genetic Approaches for the Investigation of Neutral Lipid Metabolism.Review of 3-year outcomes of a very-low-energy diet-based outpatient obesity treatment programme.Targeting adipose tissue in the treatment of obesity-associated diabetes.Commentary on prevention a possible drug-drug interaction: is concurrent administration of orlistat and pioglitazone increase the risk of durg-induced hepatotoxicity?Smart conjugated polymer nanocarrier for healthy weight loss by negative feedback regulation of lipase activity.
P2860

Benefit-risk assessment of orlistat in the treatment of obesity.

Item
http://www.wikidata.org/entity/Q38234236
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Benefit-risk assessment of orlistat in the treatment of obesity.
@en
type
label
Benefit-risk assessment of orlistat in the treatment of obesity.
@en
prefLabel
Benefit-risk assessment of orlistat in the treatment of obesity.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P356
P1433
P1476
Benefit-risk assessment of orlistat in the treatment of obesity.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921